Home » Astellas, XenoPort Announce Results from Trial for Restless Legs Syndrome
Astellas, XenoPort Announce Results from Trial for Restless Legs Syndrome
Astellas Pharma Inc. and XenoPort, Inc. announced preliminary top-line results from a Phase 2 clinical trial of ASP8825/XP13512 for the treatment of symptoms in moderate-to-severe primary restless legs syndrome patients.
MarketWatch
MarketWatch
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May